ArticleJournal of inflammation research2026
Elucidating the Mechanism of Fusu Agent Against Sepsis-Induced Acute Respiratory Distress Syndrome via an Integrated Approach Combining Network Pharmacology, Molecular Dynamics Simulations, and Experimental Validation.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Outcomes reported in randomized controlled trials of traditional Chinese medicine for acute pharyngitis: a scoping review.Frontiers in pharmacology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis represents a critical medical condition that frequently progresses to acute respiratory distress syndrome (ARDS). While the traditional Chinese medicine Fusu agent (FSHJ) is clinically effective, its precise mechanisms in sepsis-induced ARDS remain unclear. Methods: To elucidate the therapeutic mechanisms of FSHJ in sepsis-induced ARDS, we implemented an integrated multi-method strategy combining network pharmacology, molecular dynamics simulations (MDS), liquid chromatography-mass spectrometry (LC-MS), and in vivo validation. Active compounds and targets of FSHJ were identified from Batman-TCM 2.0, followed by protein-protein interaction network construction via STRING. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) enrichment analyses were performed using clusterProfiler in R. Molecular docking with AutoDock Vina assessed binding affinities, and MDS with GROMACS verified complex stability. LC-MS confirmed the predicted bioactive components, while animal models experimentally validated the associated signaling pathways. Results: A total of 537 shared therapeutic targets were pinpointed among FSHJ, ARDS, and sepsis. Integrative assessments of protein-protein interaction (PPI) networks along with GO and KEGG enrichment analyses highlighted that the anti-sepsis-induced ARDS activity of FSHJ is predominantly mediated through inflammatory response regulation. Docking simulations combined with molecular dynamics analyses demonstrated that the key bioactive compound quercetin exhibited robust and sustained interactions with specific protein targets. LC-MS analyses further authenticated the presence of anticipated active compounds, particularly the glycoside derivative quercetin-3β-D-glucoside. Furthermore, all three doses of FSHJ effectively alleviated pathological lung tissue damage and systemic inflammatory responses induced by Conclusion: Our findings indicate that FSHJ exerts protective effects in an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.